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Emerging data on the teratogenic potential of antiepileptic drugs
(AEDs), in particular valproate, have resulted in a prescribing shift
towards lamotrigine and levetiracetam in women of childbearing
age with epilepsy.1,2 Over the last 20 years prescription of
lamotrigine to women of childbearing potential has increased ten-
fold in the UK, with a reduction in valproate prescription of one
third.1 However, use of lamotrigine and levetiracetam during
pregnancy can be associated with other difﬁculties. It is widely
documented that lamotrigine clearance increases by up to 330% in
pregnancy3with studies showing an increase in seizure frequency in
39–45% of women.4,5 Early studies have also shown that serum levels
of levetiracetam fall by 40–62% during the second and third
trimesters of pregnancy.6–8 In contrast to lamotrigine very little is
known about whether this is clinically signiﬁcant. To date, the largest
report of seizure control in women taking levetiracetam during
pregnancy included only 19 patients.7 Although increased seizure
frequency was observed in seven women, the authors felt that no
deﬁnite conclusion could be drawn between declining levetiracetam
dose/concentration ratios and seizure breakthrough. Two other
small studies are complicated by inclusion of women taking both
lamotrigine and levetiracetam as part of polytherapy regimens.6,8
In a cohort of 39 women in Northern Ireland identiﬁed through
the UK Epilepsy and Pregnancy Register, who took levetiracetam as
monotherapy during pregnancy, we observed deterioration or
relapse of seizures in 30.8% (12) of women. Seizure control was
unchanged in twenty women (51.3%) and improved in seven
(17.9%). Five women discontinued AED treatment on conﬁrmation of
pregnancy and have not been included in this study. Eleven (91.7%)
of the twelve women whose seizures deteriorated had active
epilepsy prior to pregnancy. In contrast 21 of 27 (77.8%) of those
noting an improvement in seizure control or no change in seizure
frequency had active epilepsy prior to pregnancy. Active epilepsy is
deﬁned as a person whose most recent seizure has occurred within
the last 2 years.9One patient who had been seizure free for four years
prior to pregnancy had a relapse of simple partial seizures at 35
weeks gestation. The mean number of previous AEDs was 2.1, 1.78
and 1.57 for those whose seizure control deteriorated, did not
change and improved respectively. Mean levetiracetam dose was
1596 mg prior to pregnancy. Levetiracetam dose was increased
during pregnancy in 48.7% of patients (mean dose increase of
592 mg). Serum drug levels were checked in 41% of women but these
were one off levels taken routinely at the time of ﬁrst antenatal
appointment in the majority of cases.
This report raises some concerns about deteriorating seizure
control in women taking levetiracetam during pregnancy, particu-
larly for those women with active epilepsy prior to pregnancy. The
number with a deterioration in seizure control at over 30% of women
is towards the upper end of the expected range of 15–32%.10–12 In1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.05.004contrast to the number of studies examining seizure control in
women taking lamotrigine in pregnancy, studies of levetiracetam in
this situation are few and of insufﬁcient quality to allow meaningful
conclusions to be made. The increasing use of this broad spectrum
AED in women of childbearing age makes this an important issue to
clarify. Our preliminary ﬁndings, together with the paucity of
evidence in this area, clearly highlight the need for further research
to guide clinicians treating women taking levetiracetam in
pregnancy.
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